Objective
The incidence of Cardiovascular Disease (CD) claims worldwide 17.1 million lives a year, with an estimated 31% of all deaths globally and a EU cost of 139 billion euros. Up to 40% of all deaths occur among the elderly. In spite of all medical efforts, the 5-year mortality was reduced significantly less than that of malignant diseases. This highlights the urgent need to overcome the difficulties associated with present pharmacological therapies (i.e. drug instability, and unspecific targeting) by developing new ground-breaking therapeutic strategies that go far beyond any current regimens. New approaches for safe, efficient, and heart-specific delivery of therapeutics are strongly required. CUPIDO is envisioned to meet these critical needs by providing an unconventional and effective strategy based on nanoparticle-assisted delivery of clinically available and novel therapeutics to the diseased heart. In particular, CUPIDO will develop innovative bioinspired hybrid nanoparticles formulated as biologicals delivery, which are i) biocompatible and biodegradable, ii) designed for crossing biological barriers, and iii) guidable to the heart. A combination of multidisciplinary manufacturing and validation approaches will be employed, bringing the envisioned product beyond the currently available clinical and day-to-day management of CD individuals. Scale-up production, and respect of medical regulatory requirements will allow CUPIDO to deliver a final product for future late pre-clinical and clinical studies. Altogether, CUPIDO will foster the translation of nanomedical applications toward the cardiac field, which although still in its start, offers great potential to overcome the limitations associated to the currently pharmacological treatments.
Fields of science
- engineering and technologyenvironmental biotechnologybioremediationbioreactors
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesclinical medicineoncology
- engineering and technologynanotechnologynano-materials
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
00185 Roma
Italy
See on map
Participants (12)
10117 Berlin
See on map
0164 Oslo
See on map
SW7 2AZ London
See on map
153 43 Agia Paraskevi (Athina)
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
33100 Udine
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
CB4 0WS Cambridge
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
91380 Chilly Mazarin
See on map
38292 La Verpilliere
See on map
48018 Faenza
See on map
Participation ended
1226 Luxembourg
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
43124 Parma Pr
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20146 Milano
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.